Welcome!

News Feed Item

Bruker Announces Powerful New Mass Spectrometry Systems and Solutions for Life-Science Research, Clinical Research, Biopharma and Applied Markets

At the 62nd ASMS Conference on Mass Spectrometry and Allied Topics today, Bruker Corporation (NASDAQ:BRKR) today announced mass spectrometry-based product introductions for life-science research and proteomics, for clinical research, for pharma/biopharma/CRO customers, as well as for applied and industrial markets. The new systems and solutions are designed to deliver confident analyses with significantly enhanced performance, productivity and versatility.

impact(TM) II Mass Spectrometer (Photo: Business Wire)

impact(TM) II Mass Spectrometer (Photo: Business Wire)

Major Bruker Innovations at ASMS 2014:

  • New impact II ™ ultra-high resolution QTOF mass spectrometer with industry-leading further performance improvements
  • A breakthrough, new 21 Tesla magnet for ultra-high field Fourier Transform Mass Spectrometry (FTMS), described in a separate joint press release together with NHMFL
  • Opening the next chapter in proteomics, the unique impact II now enables for the first time ever fast, intact protein profiling of over 1,000 proteoforms in a single, less than 30 minute UHPLC-UHR-QTOF run
  • New multi-OMICS platform increasing productivity, versatility, and deeper biological insights, including full MaxQuant software support and new Compass™ PathwayScreener™ software
  • New ToxScreener™ solution for comprehensive forensic toxicology on unknowns
  • European launch of Toxtyper™ 1.1, a robust and easy to use forensic and clinical research solution for routine, fast, push-button toxicology on approximately 900 compounds
  • ASMS debut of new autoflex™ speed MALDI TOF(/TOF) system with Bruker 2 kHz smartbeam™-II laser to enhance productivity in protein analysis, MALDI imaging and MALDI Biotyper applications

The new research capabilities, analytical utility and productivity will be presented in Bruker’s ASMS users’ symposium, breakfast workshops, and hospitality suite with emphasis on the following market/applications areas: systems biology, proteomics and metabolomics; biologics & pharmaceuticals; MALDI molecular imaging for pathology research and drug development; petroleomics, energy and industrial applications; applied markets including food safety, forensics and toxicology; as well as MALDI Biotyper-based clinical microbiology. The following sections describe the new Bruker products in more detail:

impact™ II Mass Spectrometer

The new impact II system is the latest innovation in Bruker’s unique UHR-QTOF (ultra-high resolution Qq-time-of-flight) mass spectrometry product line, now with industry-leading >50,000 Full-Sensitivity Resolution (FSR). It offers further enhanced analytical performance levels for all applications where trace analysis from complex, high-background matrices is a challenge – such as proteomics, biomarker research, identification of impurities, or residue screening.

Due to its industry-leading sensitivity, broad mass-transfer ion optics and fast 50 Gbit/sec sampling technology, a dynamic range of 5 orders of magnitude is achieved at UHPLC speeds, with up to 50 Hz spectrum acquisition. The impact II features industry-leading isotopic pattern accuracy, a prerequisite for automated, reliable molecular formula determination of low abundance compounds in nano- and UHPLC peaks.

The enhanced capabilities and versatility of this novel UHR-QTOF drive more productivity for all accurate mass , high dynamic range applications in academia and industry, including:

  • Faster and cost-effective analysis of sub-units of monoclonal antibodies, which can now be fully isotope resolved.
  • Sustainable identification and quantification performance for in-depth quantitative analysis of proteomics samples, including bottom-up proteomics, glycomics and the identification of PTMs
  • High-throughput proteoform screening of intact proteins with isotopic resolution up to 30 kDa. This unique assay allows the screening of well over 1,000 proteoforms in a single 20-30 min UHPLC-UHR-QTOF run. This breakthrough in proteomics is expected to provide an enabling technology for accelerated biomarker identification and validation, and for faster progress towards clinical proteomics.
  • Deep insight into complex metabolomics samples in targeted and non-target analysis by integrated workflows using ProfileAnalysis™ software plus the new Compass PathwayScreener software to pinpoint biomarkers.
  • Better selectivity and specificity for the new Bruker solution in forensic toxicology, ToxScreener, which comes with accurate mass libraries developed together with leading forensic toxicology laboratories.
  • Unique Instant Expertise™ software for intelligent self-optimizing MS/MS acquisition to establish optimal experimental conditions independent of sample amount or complexity. This translates into higher productivity and expert-caliber results - the first time.

These features ensure that the impact II delivers the fastest time-to-success for customers across a broad applications ranging from small molecule identification and characterization; to food safety, forensic and toxicology screening, metabolomics, pharmaceuticals, and bottom-up proteomics, proteoform screening to antibody analysis.

Multi-OMICS Knowledge Generation Platform

Bruker is driving the quest for deeper insights and taking ‘omics’ knowledge generation to new heights with the new additions improving productivity and versatility in areas such as bottom-up proteomics, glycomics, quantitative proteomics, intact protein analysis, post-translational modifications and metabolomics.

“We have been using the Impact since almost a year for routine shot-gun bottom-up proteomics. In combination with the CaptiveSpray nanoBooster, the instrument has provided an excellent level of sustainable performance, being capable of delivering untouched performance for over 6-8 weeks of 24/7 use. This is of tremendous importance for the success of our label-free measurement campaigns,” said Professor Alain Van Dorsselaer, LSMBO in Strassbourg, France.

To strengthen its bioinformatics platform, Bruker has collaborated with developers in the group of Professor Matthias Mann to add support for Bruker UHR-QTOF data to the state-of-the-art quantitative proteomics MaxQuant software designed for analyzing large mass-spectrometric data sets. It is specifically aimed at high-resolution MS data. Several labeling techniques as well as label-free data processing workflows are supported and in addition MaxQuant enables researchers to utilize the full potential of mass spectrometry driven proteomics in multi-OMICS approaches.

In metabolomics there is an increasing need for efficient data processing tools, and Bruker has strengthened its bioinformatics offering with Compass™ PathwayScreener software to provide a new layer of insight into metabolomics samples. With the new Compass PathwayScreener, users can get twice the results, performing pathway-driven, targeted metabolomics analysis on the same dataset used for non-targeted data mining. The PathwayScreener workflow can be integrated with Bruker’s market-leading multi-OMICS bioinformatics platform ProfileAnalysis™ for non-targeted metabolomics and label free proteomics studies.

Professor Jörn Kalinowski, at the Center for Biotechnology in Bielefeld, Germany, stated: “Using Compass PathwayScreener we were able to elucidate novel influences of mutants on metabolic networks in Corynebacterium glutamicum.”

In addition, Bruker is collaborating with the University of Alberta to facilitate the development of high-resolution tandem MS libraries for improved workflows in metabolomics. Professor Liang Li explained: “As a co-PI of the Human Metabolome Database (HMDB) project, my laboratory generated the original MS/MS spectral library of about 800 human metabolites using low-resolution triple quadrupole mass spectrometry. We are delighted to collaborate with Bruker to produce a new Human Metabolite MS/MS spectral library with much improved spectral quality. This library, along with an automated acquisition and processing strategy, allows users to identify metabolites very quickly with high confidence.”

Dr. Ole Vorm, the Bruker Daltonics Vice President for the Life-Science Research & Proteomics business unit, commented: “The new products deliver outstanding and robust performance in a very accessible and cost-effective platform. We are conscious of enhancing the reach and capabilities of UHF-QTOF and nano-ESI such that we make this innovative technology readily available and accessible - also for biologists who may not be mass-spec experts. Finally, our proteomics customers are excited about our breakthrough, rapid proteoform screening technology on the impact II, as well as its about 50% higher resolution for bottom-up proteomics, at full sensitivity and under UHPLC fast analysis conditions.”

ToxScreener, a Forensic Toxicology Solution based on Accurate Mass, High Dynamic Range LC-MS/MS

The ToxScreener, a new accurate mass, high dynamic range forensic toxicology solution for Bruker QTOF systems, incorporates broadband CID (bbCID) acquisition to provide a rapid and reliable way for scientists to confidently screen for hundreds or even thousands of known or previously unknown compounds of forensic relevance, delivering the highest degree of confidence, and data that is defensible in court.

The ToxScreener enables forensic toxicologists to keep up with the detection and identification of both the ‘traditional, established’ drugs of abuse, as well to detect new designer drugs that are rapidly emerging across the globe. At the heart of the ToxScreener, is a high quality, accurate mass database covering drugs of forensic relevance allowing users to attain enhanced levels of confirmation for conclusive identification compared to alternative screening techniques. The Bruker ToxScreener bbCID accurate mass forensic database was developed in close collaboration with toxicologists at the forensic institutes at the universities of Freiburg, Germany and Helsinki, Finland.

Professor Ilkka Ojanperä of the Laboratory of Forensic Toxicology at the University of Helsinki, said: “We have applied the bbCID concept using Bruker LC-TOF-MS for general forensic drug screening in urine since 2010. In 2013, we switched to the newest UHPLC-UHR-QTOF mass spectrometry technology to attain enhanced sensitivity for drugs-of-abuse and designer drug forensic screening, covering critical low concentration compounds like THC acid, buprenorphine, LSD, and synthetic cannabinoids. This approach has been well received amongst our customers, being an even bigger success than we expected, such that immunological methods in our laboratory have now been replaced by the Bruker QTOF bbCID workflow. The bbCID concept has been carefully validated against spectral library comparison, and it has proven to deliver equal confidence, but with a much higher efficiency, significantly increasing our productivity. Our forensic screening method has now been accredited by the Finnish Accreditation Service.”

High-throughput, Robust Toxtyper 1.1 Solution Automatically Analyzes for 900 Known Toxicology Target Compounds in 12 Minutes

The new Toxtyper 1.1 routine analytical solution includes novel library identification algorithms and reporting with a high-quality library update to over 900 target compounds. In addition, the Toxtyper 1.1 workflow now also comes with a targeted drugs-of-abuse sub-library. Key technologies to achieve robust and reliable toxicology identification performance include continuous, zero-delay positive/negative ion switching, high MS/MS specificity and novel, on-the-fly MS3 confirmation. The new Toxtyper 1.1 search algorithms now also are fully compatible with the recently published “Maurer/Wissenbach/Weber LC-MSn library of Drugs, Poisons and their Metabolites”, an ion trap library which holds over 1,000 parent compounds and 2,700 metabolites.

Novel software tools for automated assignment of structures to fragment ions offer additional metabolites identification and structure verification by MSn. Toxtyper 1.1 now supports sample preparation SOPs for high sensitivity detection of drugs in urine and serum. Toxtyper is a Research Use Only solution presently available only in Europe in selected countries. For more information on the amaZon speed mass spectrometer, please visit www.bruker.com

ASMS Debut of autoflex™ speed MALDI-TOF(/TOF) with 2 kHz Smartbeam™ Laser

The updated autoflex speed mass spectrometer incorporates of numerous advancements to further enhance data quality, acquisition speed, class-leading mass and dynamic range, all with robust and efficient performance. It further extends the applications of MALDI TOF/TOF in protein sequencing, biomarker discovery, polymer analysis, lipid and glycan analysis, molecular imaging, as well as in high-throughput MALDI Biotyper microbiological identification. The autoflex speed incorporates the patented smartbeam™-II laser, now with up to 2 kHz repetition rate and true-pixel image resolution at 20 µm, along with other features that enhance its capabilities including:

  • Unique FAST-SRM mode for single reaction monitoring in imaging drugs and metabolites in tissue.
  • Expanded high-resolution mass range for polymers and top-down, intact protein sequencing for long sequence readouts.
  • FlashDetector™ technology to increase resolution and prevent signal saturation for complex samples
  • Self-cleaning Ion Source cleans the source in minutes to improve up-time with minimal operator maintenance.
  • Optimized software packages for numerous applications e.g. protein, peptide or polymer analysis, as well as MALDI imaging, clinical research and the MALDI Biotyper IVD-CE workflow.

About Bruker Corporation

Bruker Corporation is a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analysis. For more information about Bruker Corporation (NASDAQ:BRKR), please visit www.bruker.com.

More Stories By Business Wire

Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
We are seeing a major migration of enterprises applications to the cloud. As cloud and business use of real time applications accelerate, legacy networks are no longer able to architecturally support cloud adoption and deliver the performance and security required by highly distributed enterprises. These outdated solutions have become more costly and complicated to implement, install, manage, and maintain.SD-WAN offers unlimited capabilities for accessing the benefits of the cloud and Internet. ...
Dion Hinchcliffe is an internationally recognized digital expert, bestselling book author, frequent keynote speaker, analyst, futurist, and transformation expert based in Washington, DC. He is currently Chief Strategy Officer at the industry-leading digital strategy and online community solutions firm, 7Summits.
As IoT continues to increase momentum, so does the associated risk. Secure Device Lifecycle Management (DLM) is ranked as one of the most important technology areas of IoT. Driving this trend is the realization that secure support for IoT devices provides companies the ability to deliver high-quality, reliable, secure offerings faster, create new revenue streams, and reduce support costs, all while building a competitive advantage in their markets. In this session, we will use customer use cases...
Daniel Jones is CTO of EngineerBetter, helping enterprises deliver value faster. Previously he was an IT consultant, indie video games developer, head of web development in the finance sector, and an award-winning martial artist. Continuous Delivery makes it possible to exploit findings of cognitive psychology and neuroscience to increase the productivity and happiness of our teams.
When building large, cloud-based applications that operate at a high scale, it's important to maintain a high availability and resilience to failures. In order to do that, you must be tolerant of failures, even in light of failures in other areas of your application. "Fly two mistakes high" is an old adage in the radio control airplane hobby. It means, fly high enough so that if you make a mistake, you can continue flying with room to still make mistakes. In his session at 18th Cloud Expo, Le...
Machine learning has taken residence at our cities' cores and now we can finally have "smart cities." Cities are a collection of buildings made to provide the structure and safety necessary for people to function, create and survive. Buildings are a pool of ever-changing performance data from large automated systems such as heating and cooling to the people that live and work within them. Through machine learning, buildings can optimize performance, reduce costs, and improve occupant comfort by ...
DevOps tends to focus on the relationship between Dev and Ops, putting an emphasis on the ops and application infrastructure. But that’s changing with microservices architectures. In her session at DevOps Summit, Lori MacVittie, Evangelist for F5 Networks, will focus on how microservices are changing the underlying architectures needed to scale, secure and deliver applications based on highly distributed (micro) services and why that means an expansion into “the network” for DevOps.
Is it possible to migrate 100% of your data ecosystem to the cloud? Join Joe Caserta as he takes you on a complete journey to digital transformation mapping out on-prem data footprint and walking it to the cloud. Joe will also explain how the modern ecosystem supports Artificial Intelligence and will include business use cases to back each of his insights.
René Bostic is the Technical VP of the IBM Cloud Unit in North America. Enjoying her career with IBM during the modern millennial technological era, she is an expert in cloud computing, DevOps and emerging cloud technologies such as Blockchain. Her strengths and core competencies include a proven record of accomplishments in consensus building at all levels to assess, plan, and implement enterprise and cloud computing solutions. René is a member of the Society of Women Engineers (SWE) and a m...
With 10 simultaneous tracks, keynotes, general sessions and targeted breakout classes, @CloudEXPO and DXWorldEXPO are two of the most important technology events of the year. Since its launch over eight years ago, @CloudEXPO and DXWorldEXPO have presented a rock star faculty as well as showcased hundreds of sponsors and exhibitors! In this blog post, we provide 7 tips on how, as part of our world-class faculty, you can deliver one of the most popular sessions at our events. But before reading...
Containers and Kubernetes allow for code portability across on-premise VMs, bare metal, or multiple cloud provider environments. Yet, despite this portability promise, developers may include configuration and application definitions that constrain or even eliminate application portability. In this session we'll describe best practices for "configuration as code" in a Kubernetes environment. We will demonstrate how a properly constructed containerized app can be deployed to both Amazon and Azure ...
Poor data quality and analytics drive down business value. In fact, Gartner estimated that the average financial impact of poor data quality on organizations is $9.7 million per year. But bad data is much more than a cost center. By eroding trust in information, analytics and the business decisions based on these, it is a serious impediment to digital transformation.
Charles Araujo is an industry analyst, internationally recognized authority on the Digital Enterprise and author of The Quantum Age of IT: Why Everything You Know About IT is About to Change. As Principal Analyst with Intellyx, he writes, speaks and advises organizations on how to navigate through this time of disruption. He is also the founder of The Institute for Digital Transformation and a sought after keynote speaker. He has been a regular contributor to both InformationWeek and CIO Insight...
In this presentation, you will learn first hand what works and what doesn't while architecting and deploying OpenStack. Some of the topics will include:- best practices for creating repeatable deployments of OpenStack- multi-site considerations- how to customize OpenStack to integrate with your existing systems and security best practices.
DXWorldEXPO LLC announced today that Kevin Jackson joined the faculty of CloudEXPO's "10-Year Anniversary Event" which will take place on November 11-13, 2018 in New York City. Kevin L. Jackson is a globally recognized cloud computing expert and Founder/Author of the award winning "Cloud Musings" blog. Mr. Jackson has also been recognized as a "Top 100 Cybersecurity Influencer and Brand" by Onalytica (2015), a Huffington Post "Top 100 Cloud Computing Experts on Twitter" (2013) and a "Top 50 C...